The North America Biomarkers Market is witnessing robust growth driven by technological advancements and rising investments in personalized medicine. According to recent estimates, the market was valued at USD 19,850 million in 2025 and is expected to reach USD 46,230 million by 2035, expanding at a CAGR of 8.1% between 2024 and 2035. The increasing adoption of biomarkers for diagnostic and prognostic applications, higher prevalence of chronic diseases, and growing pipeline of biomarker-driven clinical trials are some of the factors fueling market expansion across the region.
The economic impact of tariffs on "North America Biomarkers Market".
Market Growth Drivers
Technological Advancements in Biomarker Discovery: The integration of next-generation sequencing (NGS), high-throughput omics technologies, and improved bioinformatics tools have significantly enhanced the accuracy and speed of biomarker discovery across North America. Companies like Thermo Fisher Scientific have expanded their biomarker platforms, enabling early detection of diseases such as cancer and cardiovascular conditions, ultimately driving greater clinical uptake and commercialization of novel biomarker assays.
Rising Investments in Personalized Medicine and Companion Diagnostics: Increasing focus on precision medicine has directed both public and private investments towards biomarker-based research. In 2023, Roche invested heavily in the expansion of its companion diagnostics division in the US and Canada, supporting the development of targeted therapies and biologics. This strategic shift accelerates the adoption of biomarker-based products in clinical settings, contributing significantly to overall market growth.
Market Trends
Expansion of Multi-Omics Approaches: The industry is witnessing a shift from single biomarker tests to multi-omics approaches, integrating genomics, proteomics, and metabolomics for comprehensive disease profiling. Illumina, for example, has introduced data solutions that offer multi-omic biomarker insights, allowing healthcare providers to diagnose complex conditions more effectively and tailor individualized treatment regimens.
Increased Adoption of Digital Biomarkers and Artificial Intelligence: The emergence of digital biomarkers and AI-driven analytics is transforming the landscape of disease detection and monitoring. In early 2024, IBM Watson Health collaborated with Mayo Clinic to develop AI-powered platforms for the analysis of digital biomarkers derived from wearable devices and electronic health records, significantly improving the efficiency and reliability of predictive diagnostics.
Market Opportunity
Expanding Biomarker Applications in Immunotherapy: The growing use of biomarkers to predict patient response to immunotherapies, notably in oncology, is creating substantial opportunities for market players. Merck & Co. has accelerated collaborations with North American hospitals to validate novel immune-response biomarkers, aiming to improve patient stratification and treatment outcomes.
Unmet Needs in Neurodegenerative Disorders: There is significant potential for growth by developing biomarkers for early detection of disorders like Alzheimer's and Parkinson's disease. Companies such as Biogen are actively investing in biomarker validation and development partnerships to address these critical gaps and introduce commercially viable solutions.
North America Biomarkers Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates steady growth for the North America Biomarkers Market, starting at USD 10,200 million in 2020 and increasing to USD 19,850 million in 2025. The momentum continues through the forecast period, driven by innovations and an expanding clinical application base, reaching an impressive USD 46,230 million by 2035. The chart highlights the acceleration post-2025, reflecting increased acceptance and R&D, particularly in oncology and neurology, where biomarkers play a vital role in improved diagnostics and personalized therapies.
North America Biomarkers Market by Regional Share (%), 2025
The 2025 regional share chart indicates that the United States holds the largest market share at 75%, attributed to a mature healthcare infrastructure and heavy investment in biomarker R&D. Canada follows with 15%, leveraging robust research collaborations and government backing. Mexico commands an 8% share, witnessing rising adoption in clinical trials. Other North American regions and the Caribbean together form the remaining 2%, reflecting emerging, albeit smaller, contributions to the market growth.
Recent Developments in North America Biomarkers Market (Last 6 Months)
In February 2024, Thermo Fisher Scientific announced the acquisition of an AI-based biomarker analytics start-up aimed at enhancing their capacity to deliver integrated omics data solutions for disease detection, particularly in cancer. This move strengthens Thermo Fisher’s portfolio and facilitates quicker commercialization of companion diagnostics.
In March 2024, Roche Diagnostics launched its new multi-modal biomarker panel for early Parkinson’s disease detection in North America. The panel is designed for use in routine clinical diagnostics and is validated in collaborations with major academic hospitals, aiming to address unmet needs in neurodegenerative disease management.
In April 2024, Illumina entered into a partnership with Toronto’s Centre for Proteomics to advance development and validation of blood-based multi-omic liquid biopsy tests for early cancer detection. This collaboration accelerates the availability of non-invasive tests and expands Illumina’s leadership in liquid biopsy-based biomarker innovation.
Press Releases